Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharming Group ( (PHAR) ) has provided an announcement.
On May 7, 2026, Pharming Group announced that it is presenting a series of data sets on its PI3Kδ inhibitor leniolisib at the Clinical Immunology Society’s 2026 Annual Meeting in New Orleans, covering May 6–9. The program includes interim outcomes from a long-term extension study in pediatric APDS patients aged 4–11, real-world clinical experience from expanded-access use in Common Variable Immunodeficiency and CVID-like disorders, and registry and symptom data that deepen understanding of APDS and related primary immunodeficiencies.
The company highlighted that two phase II trials are in progress to formally assess leniolisib’s safety and tolerability in CVID and other primary immunodeficiencies with immune dysregulation beyond APDS, with results expected in the second half of 2026. These disclosures underscore Pharming’s strategy to broaden leniolisib’s clinical footprint beyond its current approvals, potentially expanding its addressable rare disease market and reinforcing its positioning as a specialist in targeted therapies for complex immune disorders.
The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
The score is driven primarily by improving financial performance (return to profitability and stronger cash flow) and supportive technicals (price above key moving averages with positive momentum). These positives are offset by a very expensive valuation (extremely high P/E) and the risk implied by recent TTM revenue contraction and thin net margins.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a Netherlands-based biopharmaceutical company focused on rare diseases, developing and commercializing targeted therapies for primary immunodeficiencies and other conditions characterized by immune dysregulation. Its lead product, leniolisib, is an oral PI3Kδ inhibitor approved in multiple countries as the first targeted treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), with a growing global market in ultra-rare immunology.
Average Trading Volume: 18,646
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B
For detailed information about PHAR stock, go to TipRanks’ Stock Analysis page.